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Abstract
Rasmussen syndrome is an intractable epilepsy with a putative causal relation with cellular and humoral autoimmunity.
Almost half of the patients have some preceding causative factors, with infections found in 38.2%, vaccinations in 5.9% and
head trauma in 8.9% of Japanese patients. In a patient with seizure onset after inﬂuenza A infections, cross-reaction of the
patient’s lymphocytes with GluR12 and inﬂuenza vaccine components was demonstrated by lymphocyte stimulation test.
Database analyses revealed that inﬂuenza A virus hemagglutinin and GluR12 molecules contain peptides with the patient’s
HLA class I binding motif (HLA 2 A*0201). The relative risks of HLA class I genotypes for Rasmussen syndrome are 6.1
(A*2402), 6.4 (A*0201), 6.3 (A*2601) and 11.4 (B*4601). The relative risks of HLA class I-A and B haplotypes are inﬁnity
(A*2601 þ B*5401), 21.1 (A*2402 þ B*1501), 13.3 (A*2402 þ B*4801) and 5.1 (A*2402 þ B*5201). Some alleles and
haplotypes of HLA class I may be the risk factors in Japanese patients. Cross-reactivity of cytotoxic T lymphocytes may
contribute to the processes leading from infection to the involvement of CNS.
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Introduction
Rasmussen’s encephalitis is a slowly progressive,
autoimmune-mediated chronic inﬂammatory disease
of the CNS. The mean age of onset is 7.4 years. The
disease may be preceded by some causative factors
including infection, and the initial seizure episode
manifests various forms such as partial onset
generalized tonic-clinic (pGTC) seizures (30%),
focal motor seizures (26%) and complex partial
seizures (CPS) (26%) (Andermann 1991). One third
of the patients have preceding infections within 1
month before onset. Patients with typical Rasmussen’s
encephalitis manifest frequent intractable partial
motor seizures in the acute phase, characteristically
epilepsia partialis continua (EPC) (56%). Patients
begin to manifest EPC 1.8 years after the onset of
epilepsy, but the seizure frequency decreases markedly
in the residual stage (Andermann 1991, Bien et al.
2002b) (Figure 1). Patients in the residual stage are
affected by hemiplegia (96%), mental deterioration
(85%), visual ﬁeld defect (49%), and cortical sensory
defect (29%) (Andermann 1991). Histological exam-
ination reveals inﬁltration of T lymphocytes
and microglia cells, astrocytosis, and neuronal loss in
the lesion (Aguilar and Rasmussen 1960, Andermann
1991,Farrelletal.1995).Functionalhemispherectomy
is the only reliable therapy when the non-dominant
side is involved, but hemiparesis and hemianopsia are
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is affected, there is no effective therapy.
Viral infections were implicated as the causal agent
of Rasmussen’s encephalitis in early investigations
(Andermann 1991), and direct infection by several
candidate viruses (CMV, tick-borne encephalitis virus,
etc.) has been postulated as one of the possible
mechanisms causing the disease (Takahashi 2006)
(Figure 2).
Rogers et al. (1994) reported glutamate receptor 3
(GluR3) as an autoantigen in Rasmussen’s ence-
phalitis, and proposed autoantibodies against this
molecule to be one cause of Rasmussen’s encephalitis
(humoral autoimmune hypothesis). Their report
Figure 1. Schematic presentation of the typical clinical course of Rasmussen syndrome. After preceding infections, epileptic seizures (focal
motor seizures or partial onset generalized tonic clonic convulsions, etc.) appear, followed by progressive deterioration of clinical symptoms
and aggravation of EEGs and MRI abnormalities. In the residual stage, permanent handicap is observed, but epileptic seizures decrease.
GTC, generalized tonic clonic seizure; GluR, glutamate receptor; EPC, epilepsia partialis continua.
Figure 2. Hypotheses of autoimmune pathologies in Rasmussen syndrome. Direct viral infection hypothesis presumes that viral particles
invade the brain and cause neuronal death, etc. Humoral autoimmune hypothesis supposes that autoantibodies against neural molecules
(GluR3, etc.) play the primary roles to develop Rasmussen syndrome. Cell-mediated autoimmune hypothesis speculates that CTLs and/or
cytokines from CD4
þT cells play the primary roles. EBV, Ebstein bar virus; GluR, glutamate receptor; APC, antigen-presenting cells.
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mediated mechanism to the ﬁeld of epilepsy. Several
pathological roles of autoantibodies against GluR3
have been demonstrated, including excitotoxicity
(Levite and Hermelin 1999), complement-dependent
cell death (He et al. 1998) and membrane attack
complex (MAC) (Xiong and McNamara 2002, Xiong
et al. 2003) have been shown, although induction
of currents through GluR remains controversial
(Twyman et al. 1995, Watson et al. 2004). The
MAC is composed of several complements, and
appears to induce functional pore in cell membrane,
leading to depolarization and osmotic lysis of neurons.
These data indicate that autoantibodies can directly
cause impairment of neural functions.
On the other hand, Bien et al. (2002a) proposed the
destruction of neurons by cytotoxic T cells (CTLs) as
a new pathogenic mechanism in Rasmussen’s
encephalitis (cell-mediated autoimmune hypothesis).
Lymphocytic inﬁltration containing predominantly T
cells and sparsely B cells can be observed in surgically
resected tissues from patients with Rasmussen’s
encephalitis (Farrell et al. 1995), and local CNS
immune responses in Rasmussen’s encephalitis
include clonal expansion of T cells responding to
discrete antigen epitopes (Li et al. 1997). Peripheral
blood lymphocytes from patients are sensitized to
GluR12 (Takahashi et al. 2005). Heterogeneous
autoantibodies against neuronal molecules (including
GluR3, GluR12, neuronal acetylcholine receptor
alpha7, and munc-18) (Yang et al. 2000, Watson
et al. 2001, Takahashi et al. 2003) and glial cells
(Roubertie et al. 2005) are detected in Rasmussen
syndrome. Autoantibodies against GluR12h a v e
epitopes predominantly in intracellular domains, and
show epitope spreading evolutionally (Takahashi et al.
2003). We postulated that the autoimmune-mediated
mechanism for the development of Rasmussen
syndrome involves primarily cellular autoimmunity
mediated by cytotoxic T cells, and evolutionarily
involves humoral autoimmunity mediated by auto-
antibodies (Takahashi et al. 2003, 2005). These
autoimmune mechanisms of epileptogenesis after
infections can be classiﬁed as parainfectious mechan-
isms (Figure 3) (Takahashi 2006).
Causative factors of in patients with Rasmussen
syndrome
In our epilepsy center, 44% of Japanese patients with
Rasmussen syndrome had prior infections or vacci-
nations, and approximately 8% had head trauma as
preceding causative factors, and the frequencies are
almost same in patients with EPC and in those
without EPC (Table I) (Takahashi 2006). The
microbes causing infections were not identiﬁed in
the majority of patients, except in three patients
infected by inﬂuenza virus and one patient by
mycoplasma. Likewise, in the study conducted at
Montreal Neurological Institute, the causative
microbes were not documented except measles
(encephalitis) and varicella (Andermann 1991).
Figure 3. Involvements of CTLs and autoantibodies in the hypothetic mechanisms of the development of Rasmussen syndrome. Effecter T
cells activated by preceding infections or vaccinations reach the CNS by crossing blood brain barrier, and cross-react with neurons, etc.
resulting in apoptosis. Neuronal death leads to production of autoantibodies against CNS molecules and cytokines, which might contribute to
the further neuronal death or epileptogenesis. Fragmented neuronal molecules reach systemic circulation and sensitize lymphocytes, resulting
in production of autoantibodies in the blood. BBB, blood brain barrier; CNS, central nervous system; CTLs, cytotoxic T cells; GluR,
glutamate receptor; MAC, membrane attack complex.
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microbes are involved in the development of
Rasmussen syndrome. The contribution of molecular
mimicry between microbial and neuronal molecules
and degeneracy of T cell receptor recognition to the
development of Rasmussen syndrome (autoimmune-
mediated epilepsies) will be discussed later.
We encountered two patients who developed
Rasmussen syndrome after vaccination, although
vaccination was not reported as a causative factor in
the series of Montreal Neurological Institute. One
patient had EPC type Rasmussen syndrome. This
patient received Japanese encephalitis vaccination at
the age of 15 years. Two months after vaccination, he
had the initial epileptic seizure, and subsequently
evolved to intractable and frequent complex partial
seizures (CPSs) and EPC. MRI lesions in left frontal
lobe and autoantibodies against GluR12w e r e
detected. Focal resection of the left frontal lobe failed
to control epileptic seizures, psychiatric symptoms
and deterioration. Another patient had non-EPC type
Rasmussen syndrome. This patient received measles–
mumps–rubella triple vaccine at the age of 1 year.
Three weeks later, he was affected by aseptic
meningitis caused by the vaccination. He had
intractable epileptic seizures from the age of two,
and psychiatric symptoms (including anxiety) evolved
subsequently. At the age of 14 years, right frontal
lobectomy was conducted and successfully controlled
the seizures.
Head trauma also was not reported as a causative
factor in the patients of Montreal Neurological
Institute, but we identiﬁed three patients with
Rasmussen syndrome possibly related to preceding
head trauma. As we sometimes experience patients
withasepticmeningitisafterheadtrauma,headtrauma
may facilitate the invasion of inﬂammatory T cells into
the CNS. In patients with post-concussion syndrome
after mild head injury, focal cortical dysfunction may
occur in conjunction with the disruption of the blood
brain barrier (Korn et al. 2005).
In the following sections, infection as a causative
factor in Rasmussen syndrome will be illustrated using
a speciﬁc case in which Rasmussen syndrome
developed after inﬂuenza infection, especially focusing
on the roles of molecular mimicry and HLA class I.
A case of Rasmussen syndrome after inﬂuenza
A infection, and cross-reaction of lymphocytes
This patient, a boy, was 8 year-old at the time of this
report (Case 1). His family history was unremarkable,
with ovarian cyst in his mother and parkinsonism in
his maternal grandfather. At the age of 3 years and 11
months, he had febrile generalized convulsion follow-
ing an episode of inﬂuenza A infection that was
conﬁrmed by antigen detection from a nasal sample.
Before the inﬂuenza infection, he had no neurological
symptoms and no other preceding conditions that
might precipitate the convulsions. Soon after the
initial convulsion, at age 4, he had febrile convulsive
status of left extremities associated with repeated
inﬂuenza A infection. CSF was normal, and CT
revealed no abnormalities. At the age of 4 years and 1
month, afebrile convulsive status appeared and
phenobarbital (50mg) was prescribed. Thereafter,
his seizures became progressively intractable, in spite
of a combination of several antiepileptic drugs
(carbamazepine, zonisamide, valproic acid and
phenytoin). At the age of 5 years and 4 months,
EPC appeared after phenytoin was stopped abruptly
and clobazam was added. He was referred to our
epilepsy center for the treatment of Rasmussen
syndrome at the age of 5 years and 5 months. He
had hemiparesis of left extremities, EPC of left lower
extremity, and several partial seizures in a day
(Figure 4). After functional hemispherectomy, sei-
zures were controlled completely. At age eight, he
walked to school and attended a normal elementary
school.
At presentation, IgG-autoantibodies against
GluR12 were detected in serum and CSF samples
(Takahashi et al. 2003), but IgM-autoantibody was
negative. The stimulation index obtained in the
lymphocyte stimulation test (LST) stimulated with
homogenates containing GluR12(
3H-thymidine
Table I. Causative factors in 34 patients with Rasmussen syndrome.
EPC type Non-EPC type Total
Age of onset 6.3 ^ 5.6 8.7 ^ 8.0 7.4 ^ 6.7
Preceding infections 8 (40.0%) 5 (35.7%) 13 (38.2%)
Fever only 4 1 5
Upper respiratory infection 2 1 3
Inﬂuenza 1 2 3
Mycoplasma 0 1 1
Aseptic meningitis 1 0 1
Vaccination 1 (5.0%) 1 (7.1%) 2 (5.9%)
Head trauma 2 (10.0%) 1 (7.1%) 3 (8.8%)
None 9 (45.0%) 7(50.0%) 16(47.1%)
Total 20 14 34
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3H-thymidine
uptake) was 2.78 (Takahashi et al. 2005), and was
higher than normal controls (0.63, 1.67) tested
simultaneously (Figure 5). When LSTwas conducted
by co-stimulation with homogenates containing
GluR12 and inﬂuenza vaccine, the stimulation index
was 9.19 in this patient (Case 1 in Figure 5), and was
higher compared with other patients with Rasmussen
syndrome or other epilepsies not related to preceding
inﬂuenza infection (Cases 2–5). A synergistic increase
in stimulation index with co-stimulation (GluR12 þ
inﬂuenza vaccine) compared to GluR12 stimulation
alone was observed only in the present case. These
data suggest that the lymphocytes of this patient are
sensitized not only by inﬂuenza antigen but also by
GluR12, and that the T cell receptors of this patient
can cross-react with peptides from inﬂuenza and
GluR12.
After the T cell receptors on CTLs recognize both
the HLA class I molecule and its binding peptide
expressed on antigen presenting cells (APCs), these
CTLs are activated into cytotoxic effector cells that
are capable of invading the CNS. If through molecular
mimicry and T cell receptor redundancy, the CTLs
activated by microbial peptides are able to recognize
the HLA class I and binding peptide expressed on
neurons, then the infection-activated CTLs may
induce apoptosis of neurons. Therefore, HLA class
I is one of the key molecules that determines
autoimmune mechanisms underlying the process
leading from infection or vaccination to Rasmussen
syndrome.
HLA class I and theoretical cross-reaction
of CTLs in Case 1
In the case presented above (Case 1), HLA geno-
typing identiﬁed HLA 2 A*0201, A*2402, and
B*3501 (homo). HLA 2 A*0201 binds peptides
with the following motif: [LM] 2 x(3) 2 V 2
x(2) 2 [VL] (x, free amino acid; L, leucine; M,
methionine; V, valine). Database analyses (Genome
Net: http://www.genome.jp/) revealed this motif in
various viral molecules and neural molecules
(Figure 6). If patients with HLA 2 A*0201 are
infected by inﬂuenza Avirus, the peptide LAIMVAGL
from the hemagglutinin of inﬂuenza A is able to bind
with A*0201 expressed on APCs. CTLs with T cell
receptors that recognize A*0201 and the hemagglu-
tinin peptide (inﬂuenza A) on APCs become activated
and become effector CTLs. Theoretically, these
effector CTLs can invade the CNS, and react with
neurons expressing HLA 2 A*0201 and peptides
containing the [LM] 2 x(3) 2 V 2 x(2) 2 [VL]
motif, due to molecular mimicry and degeneracy of
T cell receptor recognition (Uemura et al. 2003).
Peptides having the HLA 2 A*0202 binding motif
are found in various neuronal molecules, such as
GluR12( LVLAVLAV, MLLIVSAV) and GluR11
(LPLDVNVV). Therefore, we hypothesize that
CTLs activated by inﬂuenza may cross-react with
neurons that express GluR12 under speciﬁc con-
ditions such as the presence of costimulators. This
hypothetic cross-reaction based on molecular mimicry
of HLA-binding motif is compatible with our data of
Figure 5. Stimulation index in lymphocyte stimulation test. Data
on the left show stimulation indices (SI) (
3H-thymidine uptake with
stimulation/control
3H-thymidine uptake) obtained in lymphocyte
stimulation test (LST) stimulated with homogenate containing
GluR12 (Takahashi et al. 2005). Data on the right show SI when
LSTwas conducted by co-stimulation with homogenates containing
GluR12 and inﬂuenza vaccine. Case 1 is the case presented in the
text, with inﬂuenza A infection as a causative factor. Case 2 is
Rasmussen syndrome with no causal relationship with inﬂuenza.
Cases 3–5 are epileptic cases (no Rasmussen syndrome) with
autoantibodies against GluR12. C1 and C2 are normal controls.
Figure 4. Clinical course of Case 1. Epilepsy occurred at the age of
four, and progressive atrophy of right hemisphere started at the age
of 5 year and 6 months. IgG-autoantibodies against GluR12 were
positive on admission, but became negative after functional
hemispherectomy that successfully controlled seizures. SPS,
simple partial seizure; CPS, complex partial seizure; EPC,
epilepsia partialis continua.
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inﬂuenza vaccine observed in Case 1 (Figure 5).
Since CTLs activated by inﬂuenza can react with a
broad spectrum of neuronal molecules, theoretically,
apoptotic lesions caused by CTLs may distribute
widely in the brain. On the other hand, possible
interactions of the activated CTLs of Case 1 with a
variety of microbial molecules (Figure 6) may explain
the symptomatic aggravation triggered by infections
other than inﬂuenza after the onset of Rasmussen
syndrome. T cell clones from type 1 diabetes patients
have been shown to react with several kinds of
microbial mimicry peptides (Uemura et al. 2003).
Similar molecular mimicry may also exists for
HLA 2 A*2402 and B*3501. These molecules also
have speciﬁc binding motifs. Database search ident-
iﬁed diverse peptides containing these speciﬁc motifs
in both microbial and neural molecules.
HLA class I in patients with Rasmussen
syndrome
We studied the genotypes of HLA class I in 16
Japanese patients with Rasmussen syndrome (EPC
type, 9; non-EPC type, 7) by PCR ampliﬁcations. The
data were analyzed statistically using Chi-square for
independence test. HLA 2 A*2402 is a popular
genotype (36.5% of Japanese population) and was
found in 77.8% of EPC type patients (p ¼ 0.016).
The frequencies of HLA 2 A*0201 and
HLA 2 A*2601 were higher in non-EPC type
patients (both 42.9%) than in Japanese population
(10.7 and 11.3%, respectively) (p ¼ 0.033 and 0.038,
respectively). HLA 2 B*5201was found more
frequently in EPC type patients (33.3%) than in
Japanese population (10.9%) (p ¼ 0.070), while
HLA 2 B*4601 was more frequent in non-EPC type
patients (28.6%) than in Japanese population (3.4%)
(p ¼ 0.025). The relative risks of various HLA class I
genotypes for Rasmussen syndrome range from 6 to
11 (Table II), which are at the same levels as systemic
lupus erythematosus (DR2) and acute anterior uveitis
(B27) (Marsh et al. 2000). The relative risks of HLA
class I-A and B haplotypes range from 5 to 1. Since
the haplotype of A*2601 þ B*5401 was not observed
in 561 Japanese subjects, the risk is inﬁnity.
The HLA class I types that have higher relative risks
may have a greater potential to induce cross-reactions
of CTLs between microbes and neurons, and
consequently may be found at higher frequencies in
patients with Rasmussen syndrome. The binding
motifs of these HLA class I types probably exist
frequently in molecules from microbes commonly
foundinJapanandinmoleculesderivedfromneurons.
Figure 6. Viral and neural molecules containing speciﬁc binding motif for HLA 2 A*0201. Viral infection of host cells leads to expression of
some parts of the viral peptides by binding with HLA classI molecule on the infected cells. CTLsexpressing T cell receptors thatrecognize the
peptide and HLA class I are activated, resulting in generation of effecter T cells. In individuals with HLA 2 A*0201, the binding motif is
[LM] 2 x(3) 2 V 2 x(2) 2 [VL] (x, free amino acid; L, leucine; M, methionine; V, valine). Database analyses (Genome Net, http://www.
genome.jp/) revealed many viral molecules containing this motif, as shown in the left column. The numbers in parentheses are sequence
numbers indicating the sites of the motif. Effecter T cells are able to cross the blood brain barrier to reach the CNS, and theoretically can
cross-react with neurons expressing the same motif on HLA class I, under speciﬁc conditions such as the presence of costimulator. Database
analyses revealed many neural molecules including NMDA-GluRs, which contain the motif, as shown in the right column.
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